**Impact statement** (Length : 1 <1minute if oral; <80 words if written)

Colon cancer patients respond weakly to available immunotherapy drugs and have poor outcomes. The abundance of immunosuppressive cells within colon cancers makes them resistant to current immunotherapies. Moreover, first-generation drugs bolster the function of cancer-killing T cells but leave immunosuppressive cells unchecked. Therefore, a two-pronged approach of enhancing T cell activity and knocking down immunosuppressive cells is necessary to generate effective anti-tumor responses. We will empower immunotherapy against resistant tumors through synergy with new drugs that deplete immunosuppressive cells.